ADVANCED METABOLITE IDENTIFICATION IN PRECLINICAL DRUG RESEARCH USING HIGH.RESOLUTION MASS SPECTROMETRY

ABSTRACT:
The identification of metabolites is essential for deciphering the pharmacokinetics, efficiency and safety of new drug candidates in preclinical research High-resolution mass spectrometry (HRMS)has emphasize as a sophisticated analytical method, providing excellent sensitivity, mass precision, and structural details crucial for metabolite characterization. This research emphasizes the use of HRMS for the detection of metabolites in in vitro and in vivo systems. Liver microsomes and animal plasma samples underwent preparation through liquid-liquid extraction and protein precipitation methods prior to analysis. ÚItra-high performance liquid chromatography unified with time-of-flight (UHPLC-TOF)and Orbitrap mass spectrometers was utilized for precise mass determination, fragmentation pattern assessment, and isotopic distribution analysis. The research productively detected various phase I and phase II metabolites (hydroxylated, glucuronidated, and sulfated variants). The increased mass resolution determined and authorised the identification of low-abundance metabolites and the difference between various isobaric compounds. The above resul was determined via HRMS which in turn provides increased sensitivity, reproducibility, and specificity when compared with conventional techniques. thereby intergrating HRMS into the pre-drug development stages increases our idea over drug metabolism mechanisms, enables forecasting of side effects, and helps with clinical study and research.
Keywords:
High-resolution mass spectrometry, preclinical research, UHPLC-TOF, Orbitrap, drug metabolism.
pharmacokinetics, phase I metabolites, phase II metabolites